PRESS RELEASE Gothenburg
15th of November 2017, 15:15
CELLINK and Takara Bio Europe AB will collaborate to evaluate bioprinting of CELLINK’s Bioink with Takara’s cells for insulin secretion by iPS derived beta cells.
The project aim is to commercialize technology where both parties would benefit from the developed application of the combined technology. The end product would be a cell-specific bioink optimized for Takaras iPS beta cells to accelerate the tissue maturation in 3D culture. The project is now initiated, and potential commercialization of results would reach the market during 2018.
About Takara Bio Europe AB
Takara Bio Europe AB, formerly Cellartis AB, a subsidiary of Takara Bio Europe SAS., is focusing on stem cell-derived products and services for drug discovery, disease modeling, and applications within regenerative medicine. The company leverages long-standing experience in stem cell handling and scaleup together with leading expertise in differentiation of cells into mature and functional human cells. Specifically, the company possesses broad expertise in human pluripotent stem cells, including both hiPSC and hESC and related media. Takara Bio Europe AB is located in state-of-the-art facilities in Göteborg, Sweden. For more information, visit our website: www.takarabio.com
CELLINK has created one of the world’s first universal Bioinks, today used by many of the world’s most wellreputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK’s universal Bioink shows excellent results and can be used in both CELLINK’s proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Mangold Fondkommission AB, tel: +46 (0) 8 5030 1550, is the Company’s Certified Adviser.
For further information, please contact:
Erik Gatenholm, CEO
Phone: +46 73 267 00 00
Gusten Danielsson, CFO
Phone: +46 70 991 86 04